Genetic variation among 82 pharmacogenes: The PGRNseq data from the eMERGE network

Clinical Pharmacology and Therapeutics

Volumn , Issue , 2016, Pages 160-169

  Bush, W S ^a   Crosslin, D R ^b   Owusu Obeng, A ^c   Wallace, J ^d   Almoguera, B ^e   Basford, M A ^f   Bielinski, S J ^g   Carrell, D S ^h   Connolly, J J ^e   Crawford, D ^a   Doheny, K F ⁱ   Gallego, C J ^b   Gordon, A S ^b   Keating, B ^e   Kirby, J ^f   Kitchner, T ^j   Manzi, S ^k   Mejia, A R ^c   Pan, V ^l   Perry, C L ^k   Peterson, J F ^f   Prows, C A ^m   Ralston, J ^h   Scott, S A ^c   Scrol, A ^h   Smith, M ^l   Stallings, S C ^f   Veldhuizen, T ^g   Wolf, W ^k   Volpi, S ⁿ   Wiley, K ⁿ   Li, R ⁿ   Manolio, T ⁿ   Bottinger, E ^c   Brilliant, M H ^j   Carey, D ^o   Chisholm, R L ^l   Chute, C G ⁱ   Haines, J L ^a   Hakonarson, H ^e   Harley, J B ^p   Holm, I A ^q   Kullo, I J ^g   Jarvik, G P ^b   Larson, E B ^h   McCarty, C A ^j   Williams, M S ^o   Denny, J C ^f   Rasmussen Torvik, L J ^l   Roden, D M ^f   Ritchie, M D ^o   more..

^a CASE WESTERN RESERVE UNIVERSITY   (United States)

^b UNIVERSITY OF WASHINGTON   (United States)

^c MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^d PENNSYLVANIA STATE UNIVERSITY   (United States)

^e CHILDREN S HOSPITAL OF PHILADELPHIA   (United States)

^f VANDERBILT UNIVERSITY SCHOOL OF MEDICINE   (United States)

^g MAYO CLINIC   (United States)

^h GROUP HEALTH RESEARCH INSTITUTE   (United States)

ⁱ JOHNS HOPKINS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^j MARSHFIELD CLINIC   (United States)

^k BOSTON CHILDREN S HOSPITAL   (United States)

^l NORTHWESTERN UNIVERSITY   (United States)

^m CINCINNATI CHILDREN'S HOSPITAL MEDICAL CENTER   (United States)

ⁿ NATIONAL HUMAN GENOME RESEARCH INSTITUTE   (United States)

^o GEISINGER HEALTH SYSTEM   (United States)

^p VETERANS AFFAIRS MEDICAL CENTER   (United States)

^q Division of Genetics and Genomics and The Manton Center for Orphan Disease Research   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ARTICLE; CONTROLLED STUDY; ELECTRONIC MEDICAL RECORD; ETHNICITY; FEMALE; GENETIC VARIABILITY; GENETIC VARIATION; GENOMICS; HUMAN; MALE; PERSONALIZED MEDICINE; PHARMACOGENETICS; PRACTICE GUIDELINE; PRIORITY JOURNAL; RACE;

EID: 84978129461     PISSN: 00099236     EISSN: 15326535     Source Type: Journal    
DOI: 10.1002/cpt.350     Document Type: Article

References (45)

1. Wang L., McLeod, H.L. & Weinshilboum, R.M. Genomics and drug response. N. Engl. J. Med. 364(12), 1144–1153 (2011).
2. Meyer, U.A., Zanger, U.M. & Schwab, M. Omics and drug response. Annu. Rev. Pharmacol. Toxicol. 53, 475–502 (2013).
3. Meyer, U.A. Pharmacogenetics — five decades of therapeutic lessons from genetic diversity. Nat. Rev. Genet. 5(9), 669–676 (2004).
4. Pulley J.M. et al. Operational implementation of prospective genotyping for personalized medicine: the design of the Vanderbilt PREDICT project. Clin. Phamacol. Ther. 92(1), 87–95 (2012).
5. Johnson, J.A. et al. Institutional profile: University of Florida and Shands Hospital Personalized Medicine Program: clinical implementation of pharmacogenetics. Pharmacogenomics. 14(7), 723–726 (2013).
6. Shuldiner A.R. et al. Implementation of pharmacogenetics: the University of Maryland Personalized Anti-platelet Pharmacogenetics Program. Am. J. Med. Genet. C Semin. Med. Genet. 166C(1), 76–84 (2014).
7. He Y.J. & McLeod, H.L. Ready when you are: easing into preemptive pharmacogenetics. Clin. Phamacol. Ther. 92(4), 412–414 (2012).
8. Caudle, K.E. et al. Incorporation of pharmacogenomics into routine clinical practice: the Clinical Pharmacogenetics Implementation Consortium (CPIC) guideline development process. Curr. Drug Metab. 15(2), 209–217 (2014).
9. Whirl-Carrillo, M. et al. Pharmacogenomics knowledge for personalized medicine. Clin. Phamacol. Ther. 92(4), 414–417 (2012).
10. Relling, M.V. & Klein, T.E. CPIC: Clinical Pharmacogenetics Implementation Consortium of the Pharmacogenomics Research Network. Clin. Phamacol. Ther. 89(3), 464–467 (2011).
11. Roden, D.M., Wilke, R.A., Kroemer, H.K. & Stein, C.M. Pharmacogenomics: the genetics of variable drug responses. Circulation. 123(15), 1661–1670 (2011).
12. Chhibber, A. et al. Genomic architecture of pharmacological efficacy and adverse events. Pharmacogenomics. 15(16), 2025–2048 (2014).
13. Klein, K. & Zanger, U.M. Pharmacogenomics of cytochrome P450 3A4: recent progress toward the “missing heritability” problem. Front. Genet. 4, 12 (2013).
14. Oetjens, M.T. et al. Assessment of a pharmacogenomic marker panel in a polypharmacy population identified from electronic medical records. Pharmacogenomics. 14(7), 735–744 (2013).
15. Deeken, J. The Affymetrix DMET platform and pharmacogenetics in drug development. Curr. Opin. Mol. Ther. 11(3), 260–268 (2009).
16. Mizzi, C. et al. Personalized pharmacogenomics profiling using whole-genome sequencing. Pharmacogenomics. 15(9), 1223–1234 (2014).
17. Esplin, E.D., Oei, L. & Snyder, M.P. Personalized sequencing and the future of medicine: discovery, diagnosis and defeat of disease. Pharmacogenomics. 15(14), 1771–1790 (2014).
18. Musunuru, K. Personalized genomes and cardiovascular disease. Cold Spring Harb Perspect Med. 5(1), a014068–a014068 (2014).
19. Mooney, S.D. Progress towards the integration of pharmacogenomics in practice. Hum Genet. 134, 459–465 (2015).
20. Ong, F.S., Lin, J.C., Das, K., Grosu, D.S. & Fan, J.-B. Translational utility of next-generation sequencing. Genomics. 102(3), 137–139 (2013).
21. Wagner, M.J. Rare-variant genome-wide association studies: a new frontier in genetic analysis of complex traits. Pharmacogenomics. 14(4), 413–424 (2013).
22. McCarty, C.A. et al. The eMERGE Network: a consortium of biorepositories linked to electronic medical records data for conducting genomic studies. BMC Med. Genomics. 4, 13 (2011).
23. Crawford, D.C. et al. eMERGEing progress in genomics-the first seven years. Front. Genet. 5, 184 (2014).
24. Gottesman, O. et al. The Electronic Medical Records and Genomics (eMERGE) Network: past, present, and future. Genet. Med. Off. J. Am. Coll. Med. Genet. 15(10), 761–771 (2013).
25. Rasmussen-Torvik, L.J. et al. Design and anticipated outcomes of the eMERGE-PGx project: a multicenter pilot for preemptive pharmacogenomics in electronic health record systems. Clin. Phamacol. Ther. 96(4), 482–489 (2014).
26. Gordon, A.S. et al. PGRNseq: a targeted capture sequencing panel for pharmacogenetic research and implementation. Pharmacogenet. Genomics. (2016); e-pub ahead of print.
27. McCarthy, D.J. et al. Choice of transcripts and software has a large effect on variant annotation. Genome Med. 6(3), 26 (2014).
28. Marciante, K.D. et al. Cerivastatin, genetic variants, and the risk of rhabdomyolysis. Pharmacogenet. Genomics. 21(5), 280–288 (2011).
29. McCarthy, M.J., Leckband, S.G. & Kelsoe, J.R. Pharmacogenetics of lithium response in bipolar disorder. Pharmacogenomics. 11(10), 1439–1465 (2010).
30. Zou, Y.-F. et al. Association of brain-derived neurotrophic factor genetic Val66Met polymorphism with severity of depression, efficacy of fluoxetine and its side effects in Chinese major depressive patients. Neuropsychobiology. 61(2), 71–78 (2010).
31. Murphy, G.M. et al. BDNF and CREB1 genetic variants interact to affect antidepressant treatment outcomes in geriatric depression. Pharmacogenet. Genomics. 23(6), 301–313 (2013).
32. Niitsu, T., Fabbri, C., Bentini, F. & Serretti, A. Pharmacogenetics in major depression: a comprehensive meta-analysis. Prog. Neuropsychopharmacol. Biol. Psychiatry. 45, 183–194 (2013).
33. Van Driest, S.L. et al. Association of Arrhythmia-Related Genetic Variants With Phenotypes Documented in Electronic Medical Records. JAMA. 315(1), 47–57 (2016).
34. Fullerton, S.M. et al. Return of individual research results from genome-wide association studies: experience of the Electronic Medical Records and Genomics (eMERGE) Network. Genet. Med. Off. J. Am. Coll. Med. Genet. 14(4), 424–431 (2012).
35. Van Driest, S.L. et al. Clinically actionable genotypes among 10,000 patients with preemptive pharmacogenomic testing. Clin Pharmacol Ther. 95(4), 423–431 (2014).
36. Bielinski, S.J. et al. Preemptive genotyping for personalized medicine: design of the right drug, right dose, right time-using genomic data to individualize treatment protocol. Mayo Clin. Proc. 89(1), 25–33 (2014).
37. Li, H. & Durbin, R. Fast and accurate short read alignment with Burrows-Wheeler transform. Bioinforma Oxf. Engl. 25(14), 1754–1760 (2009).
38. Van der Auwera, G.A. et al. Current Protocols in Bioinformatics 11.10.1–11.10.33 (eds. Bateman, A. et al.) Current protocols in bioinformatics/ editoral board, Baxevanis, A.D., et al. (John Wiley & Sons, Hoboken, NJ; 2002).
39. Zheng, X. et al. A high-performance computing toolset for relatedness and principal component analysis of SNP data. Bioinforma Oxf. Engl. 28(24), 3326–3328 (2012).
40. McLaren, W. et al. Deriving the consequences of genomic variants with the Ensembl API and SNP Effect Predictor. Bioinforma Oxf. Engl. 26(16), 2069–2070 (2010).
41. Cingolani, P. et al. A program for annotating and predicting the effects of single nucleotide polymorphisms, SnpEff: SNPs in the genome of Drosophila melanogaster strain w1118; iso-2; iso-3. Fly (Austin). 6(2), 80–92 (2012).
42. Kircher, M. et al. A general framework for estimating the relative pathogenicity of human genetic variants. Nat. Genet. 46(3), 310–315 (2014).
43. Top 100 Most Prescribed, Top Selling Drugs [Internet]. . Accessed May 5, 2015.
44. Medicine use and shifting costs of healthcare. 2014.
45. Hewett, M. et al. PharmGKB: the Pharmacogenetics Knowledge Base. Nucleic Acids Res. 30(1), 163–165 (2002).